Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hormone therapy showdown: can dydrogesterone tame teen irregular periods?

NCT ID NCT07703488

Disease control Sponsor: Guangdong Women and Children Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study looks at whether dydrogesterone, a hormone pill, works better than a common birth control pill (drospirenone and ethinylestradiol) for treating irregular, heavy, or prolonged periods in teenagers aged 10 to 19. The main goal is to see how many teens have normal cycles after six months of treatment. Researchers will also track side effects, bleeding patterns, and quality of life. The findings could help doctors choose the best hormone therapy for young people with ovulation-related bleeding problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dydrogesterone
What this could lead to
If successful, this could show that dydrogesterone is a safe and effective option for managing irregular periods in teenagers, potentially improving long-term cycle control and quality of life.
What could go wrong
This is an observational study, not a randomized trial, so results may be less reliable. The small sample size and short follow-up may limit how broadly the findings apply.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Female participants aged 10 to 19 years old with Abnormal Uterine Bleeding of Ovulatory Disorders will be enrolled.

Ages

10 to 19 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patient between 10-19 years old, already experiencing menarche and at least 6 months away from menarche * According with the criteria of Abnormal Uterine Bleeding of Ovulatory Disorders: irregular menstrual cycles (cycle interval\<21 days or\>45 days, or adjacent menstrual intervals\>90 days), prolonged menstrual periods (\>7 days), excessive menstrual flow, poor bleeding control (score\>100 on the menstrual bleeding assessment scale, or a significant increase in the frequency of changing hygiene products) within the past 3 months, and has ruled out pregnancy related and obvious structural causes. * The guardian of the subject signs the informed consent and obtains the consent of the subject. * With complete baseline clinical data: complete blood count, serum ferritin, Six types of sex hormones(FSH, LH, E2, P, T, PRL), Gynecological Sonography. Exclusion Criteria: * Coagulation disorder * Requiring long-term anticoagulant and antiplatelet therapy * Secondary Abnormal Uterine Bleeding caused by uncontrolled hyperthyroidism, hypothyroidism, hyperprolactinemia, or other endocrine diseases. * Dysfunction of kidney and liver, or a history of severe intolerance or allergy to dydrogesterone, medroxyprogesterone, or other progestogens.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abnormal uterine bleeding (AUB) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anovulation Metrorrhagia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Abnormal uterine bleeding (AUB) Ovulation dysfunction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Guangdong Women and Children Hospital

    RECRUITING

    Guangzhou, Guangong, 511400, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.